Clozapine- and olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by β-adrenoceptors

被引:31
|
作者
Ohashi, K
Hamamura, T
Lee, Y
Fujiwara, Y
Suzuki, H
Kuroda, S
机构
[1] Okayama Univ, Sch Med, Dept Neuropsychiat, Okayama 7008558, Japan
[2] Takaoka Hosp, Himeji, Hyogo, Japan
关键词
clozapine; olanzapine; noradrenaline; beta-adrenergic receptors; atypical antipsychotics; immediate-early genes; Fos; prefrontal cortex; negative symptom; schizophrenia;
D O I
10.1016/S0893-133X(00)00105-6
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The atypical neuroleptics, clozapine and olanzapine, have superior therapeutic efficacy against thr negative symptoms of schizophrenia, compared with the typical neuroleptics. Recently, it has been suggested that the ability of clozapine and olanzapine to induce Fos expression in the medial prefrontal cortex (mPFC), contribute to their therapeutic efficacy. However, the mechanisms underlying the neuropharmacological effects of clozapine and olanzapine in the mPFC remain elusive. In the present study, we demonstrate that clozapine- and olanzapine-induced Fos expression in the mPFC are inhibited by propranolol. We also show that clozapine and olanzapine induce Fos expression in the locus coeruleus. These results suggest that clozapine and olanzapine increase noradrenaline releases by stimulating noradrenergic neuronal activity in the locus coeruleus and, consequently, increased noradrenaline induce Fos expression in the Fos expression in the mPFC via beta-adrenergic receptors. This postulated sequence may be one of mechanisms by which clozapine-like atypical neuroleptics are more effective for the negative symptoms of schizophrenia. (C) 2000 American College of Neuropsychopharmacology. Published by Elsevier Science Inc. All rights reserved.
引用
收藏
页码:162 / 169
页数:8
相关论文
共 50 条
  • [1] Clozapine- and Olanzapine-induced Fos Expression in the Rat Medial Prefrontal Cortex is Mediated by β-Adrenoceptors
    Kazuyo Ohashi
    Takashi Hamamura
    Youmei Lee
    Yutaka Fujiwara
    Hiroshi Suzuki
    Shigetoshi Kuroda
    [J]. Neuropsychopharmacology, 2000, 23 : 162 - 169
  • [2] Clozapine- and Olanzapine-induced oesophagitis and haematemesis: A case report
    Chau, Edith
    Jagadheesan, Karuppiah
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (12): : 1211 - 1211
  • [3] Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine
    Sebens, JB
    Koch, T
    Ter Horst, GJ
    Korf, J
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (01) : 13 - 21
  • [4] Whole expression profile analysis of olanzapine-induced effects in the prefrontal cortex of the rat brain
    Kim, Seung-Jun
    Jo, Jae-Hoon
    Kim, Ji-Hoon
    Yeom, Hye-Jung
    Park, Hye-Won
    Hwang, Seung-Yong
    [J]. MOLECULAR & CELLULAR TOXICOLOGY, 2007, 3 (04) : 49 - 49
  • [6] Tyrosine augments acute clozapine- but not haloperidol-induced dopamine release in the medial prefrontal cortex of the rat:: An in vivo microdialysis study
    Jaskiw, GE
    Collins, KA
    Pehek, EA
    Yamamoto, BK
    [J]. NEUROPSYCHOPHARMACOLOGY, 2001, 25 (01) : 149 - 156
  • [7] Tyrosine Augments Acute Clozapine- but not Haloperidol-Induced Dopamine Release in the Medial Prefrontal Cortex of the Rat: An in vivo Microdialysis Study
    George E Jaskiw
    Keith A Collins
    Elizabeth A Pehek
    Bryan K Yamamoto
    [J]. Neuropsychopharmacology, 2001, 25 : 149 - 156
  • [8] Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia
    Schuld, A
    Kraus, T
    Hinze-Selch, D
    Haack, M
    Pollmächer, T
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 (02) : 153 - 155
  • [9] Granulocyte colony-stimulating factor plasma levels during clozapine- and olanzapine-induced granulocytopenia - Invited comment
    Wiesel, FA
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2000, 102 (02) : 155 - 155
  • [10] Bilateral lesions of the entorhinal cortex differentially modify haloperidol- and olanzapine-induced c-fos mRNA expression in the rat forebrain
    Seillier, A
    Coutureau, E
    Thiriet, N
    Herbeaux, K
    Zwiller, J
    Di Scala, G
    Will, B
    Majchrzak, M
    [J]. NEUROPHARMACOLOGY, 2003, 45 (02) : 190 - 200